GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

GSK said on Monday a new formulation of its HIV prevention and treatment drug could potentially be administered at least every four months, an improvement from the previous requirement of dosing ...

LONDON, March 30 (Reuters) - British drugmaker GSK (GSK.L), opens new tab has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive ...

Low-cost preventative HIV medication may be ready as early as 2026, as British pharmaceutical company GSK strikes a deal allowing developing countries access to generic versions.

GSK Plc, seeking to snatch market share from Gilead Sciences Inc.’s best-selling HIV pill, said its long-acting shot works just as well and lets patients replace the daily medicine with an ...

LONDON – GlaxoSmithKline's already fast-growing HIV drug business has received an important boost with the success of two major clinical studies testing a new two-drug treatment regimen to ...